Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JEFFREY B LOOMER

Allopathic & Osteopathic Physicians Internal Medicine Rheumatology

NPI
1003824442
CMS profile
45391
Location
TUCSON, AZ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$2,456.82

150 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $2,456.82 150

By paying entity

PY2021 · entire year · sorted by reported total

Page 3 of 3; records 101–150 of 150 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JEFFREY B LOOMER

NPI 1003824442 · CMS profile ID 45391

Allopathic & Osteopathic Physicians / Internal Medicine / Rheumatology

TUCSON, AZ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–150 of 150 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1003824442?year=2021&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JEFFREY B LOOMER, NPI 1003824442, CMS profile ID 45391. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–150 of 150 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1003824442?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). JEFFREY B LOOMER, NPI 1003824442, CMS profile ID 45391. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–150 of 150 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1003824442?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
JEFFREY B LOOMER, NPI 1003824442, CMS profile ID 45391, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–150 of 150 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1003824442?year=2021&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

150 matching records · $2,456.82 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 150 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 150.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Amgen Inc. $7.3105/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825397279 CMS
Amgen Inc. $18.3705/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825397327 CMS
E.R. Squibb & Sons, L.L.C. $16.8505/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783489481 CMS
AbbVie Inc. $21.8305/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795378999 CMS
Amgen Inc. $22.5805/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825397239 CMS
AbbVie Inc. $28.5205/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795378993 CMS
Genentech USA, Inc. $15.0305/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835924163 CMS
Amgen Inc. $17.0305/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825397275 CMS
GlaxoSmithKline, LLC. $16.7105/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802506277 CMS
Amgen Inc. $4.0505/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825397271 CMS
Amgen Inc. $17.8604/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825397267 CMS
GlaxoSmithKline, LLC. $16.9404/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 803091797 CMS
E.R. Squibb & Sons, L.L.C. $15.0704/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783489477 CMS
Horizon Therapeutics plc $14.7704/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 797167353 CMS
Horizon Therapeutics plc $5.5504/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 797167351 CMS
Amgen Inc. $17.4404/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825397219 CMS
AbbVie Inc. $19.7404/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795378987 CMS
Amgen Inc. $6.3904/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825397235 CMS
GlaxoSmithKline, LLC. $19.5404/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802916955 CMS
AbbVie Inc. $21.2904/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795378983 CMS
Amgen Inc. $18.7804/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825397323 CMS
Horizon Therapeutics plc $5.7303/31/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 797167349 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $20.8303/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763464472 CMS
Genentech USA, Inc. $15.7303/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835924159 CMS
E.R. Squibb & Sons, L.L.C. $19.9003/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783489465 CMS
GlaxoSmithKline, LLC. $8.9703/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802951349 CMS
Amgen Inc. $17.7803/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825397263 CMS
Horizon Therapeutics plc $18.0303/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 797167347 CMS
AbbVie Inc. $18.0903/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795378977 CMS
Amgen Inc. $20.7603/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825397231 CMS
Amgen Inc. $7.2003/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825397259 CMS
Amgen Inc. $12.7602/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825397319 CMS
Amgen Inc. $5.6902/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825397255 CMS
Amgen Inc. $5.3202/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825397315 CMS
GlaxoSmithKline, LLC. $13.9602/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802301211 CMS
Amgen Inc. $20.1902/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825397311 CMS
E.R. Squibb & Sons, L.L.C. $21.4602/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783489455 CMS
Horizon Therapeutics plc $15.9002/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 797167345 CMS
Amgen Inc. $6.2902/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825397307 CMS
Amgen Inc. $22.4802/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825397199 CMS
Amgen Inc. $7.4101/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825397227 CMS
AbbVie Inc. $15.7601/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795378971 CMS
Horizon Therapeutics plc $5.1901/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 797167343 CMS
Amgen Inc. $27.8201/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825397303 CMS
AbbVie Inc. $16.1501/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795378965 CMS
GENZYME CORPORATION $21.2401/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843452213 CMS
E.R. Squibb & Sons, L.L.C. $15.7101/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783489449 CMS
Amgen Inc. $6.8501/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825397215 CMS
GlaxoSmithKline, LLC. $16.8801/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 801616911 CMS
Ferring Pharmaceuticals Inc. $17.2601/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 771566758 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $4,017.30 248
PY2020 $2,154.91 122
PY2021 $2,456.82 150
PY2022 $2,968.12 133
PY2023 $3,723.34 150
PY2024 $2,911.27 126
PY2025 $2,417.33 98

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $311,957.07 52
PY2024 Principal investigator $172,959.27 19
PY2023 Principal investigator $107,905.20 21
PY2022 Principal investigator $177,961.75 72
PY2021 Principal investigator $467,835.49 146
PY2020 Recipient $30.60 1
PY2020 Principal investigator $315,771.49 120
PY2019 Principal investigator $285,499.54 114

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

52 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Janssen Research & Development, LLC $2,766.40 12/19/2025 Non-covered Recipient Entity
Arizona Arthritis and Rheumatology Associates
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175165155
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $8,001.24 12/17/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND
A Multi-Center, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects with Active Psoriatic Arthritis Stratified by Prior Biologic Use (LATITUDE-PsA-3002 No dispute reported 06/30/2026 1223289898
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $100.00 12/01/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND
A Multi-Center, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects with Active Psoriatic Arthritis Stratified by Prior Biologic Use (LATITUDE-PsA-3002 No dispute reported 06/30/2026 1223288915
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,709.72 12/01/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND
A Multi-Center, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects with Active Psoriatic Arthritis Stratified by Prior Biologic Use (LATITUDE-PsA-3002 No dispute reported 06/30/2026 1223289132
Principal investigator 1 Janssen Research & Development, LLC $230.00 11/27/2025 Non-covered Recipient Entity
Arizona Arthritis and Rheumatology Associates
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175165470
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,752.32 10/15/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND
A Multi-Center, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects with Active Psoriatic Arthritis Stratified by Prior Biologic Use (LATITUDE-PsA-3002 No dispute reported 06/30/2026 1223287003
Principal investigator 1 Janssen Research & Development, LLC $75.00 10/13/2025 Non-covered Recipient Entity
Arizona Arthritis and Rheumatology Associates
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175165231
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $150.00 10/08/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND
A Multi-Center, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects with Active Psoriatic Arthritis Stratified by Prior Biologic Use (LATITUDE-PsA-3002 No dispute reported 06/30/2026 1223286547
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $6,725.42 10/01/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND
A Multi-Center, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects with Active Psoriatic Arthritis Stratified by Prior Biologic Use (LATITUDE-PsA-3002 No dispute reported 06/30/2026 1223286159
Principal investigator 1 Janssen Research & Development, LLC $2,107.00 09/29/2025 Non-covered Recipient Entity
Arizona Arthritis and Rheumatology Associates
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175165837
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $4,189.90 09/02/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH PLLC
A Multi-Center, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects with Active Psoriatic Arthritis Stratified by Prior Biologic Use (LATITUDE-PsA-3002 No dispute reported 06/30/2026 1223284697
Principal investigator 1 Janssen Research & Development, LLC $230.00 08/28/2025 Non-covered Recipient Entity
Arizona Arthritis and Rheumatology Associates
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175164819
Principal investigator 1 Janssen Research & Development, LLC $230.00 08/28/2025 Non-covered Recipient Entity
Arizona Arthritis and Rheumatology Associates
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175166115
Principal investigator 1 Janssen Research & Development, LLC $75.00 08/06/2025 Non-covered Recipient Entity
Arizona Arthritis and Rheumatology Associates
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175165305
Principal investigator 1 Janssen Research & Development, LLC $416.00 08/06/2025 Non-covered Recipient Entity
Arizona Arthritis and Rheumatology Associates
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175165697
Principal investigator 1 Amgen Inc. $10,000.00 08/01/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH
A Multicenter, Open-Label, Long-term, Extension Study to Evaluate the Safety and Tolerability of Dazodalibep in Participants With Sjgren's Syndrome (SS) No dispute reported 06/30/2026 1246639263
Principal investigator 1 Amgen Inc. $56,088.80 07/01/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjgren's Syndrome With Moderate-to-severe Systemic Disease Activity No dispute reported 06/30/2026 1246639287
Principal investigator 1 Janssen Research & Development, LLC $437.00 06/30/2025 Non-covered Recipient Entity
Arizona Arthritis and Rheumatology Associates
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175165566
Principal investigator 1 Janssen Research & Development, LLC $3,052.40 06/30/2025 Non-covered Recipient Entity
Arizona Arthritis and Rheumatology Associates
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175165588
Principal investigator 1 Janssen Research & Development, LLC $230.00 06/23/2025 Non-covered Recipient Entity
Arizona Arthritis and Rheumatology Associates
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175165881
Principal investigator 1 Eli Lilly and Company $67,703.00 06/16/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH
A PHASE 2A, SINGLE-ARM STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3541860 IN ADULT PARTICIPANTS WITH MODERATELY-TO-SEVERELY ACTIVE RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 1187877147
Principal investigator 1 Janssen Research & Development, LLC $2,341.00 05/28/2025 Non-covered Recipient Entity
Arizona Arthritis and Rheumatology Associates
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175165023
Principal investigator 1 Janssen Research & Development, LLC $230.00 05/28/2025 Non-covered Recipient Entity
Arizona Arthritis and Rheumatology Associates
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175165900
Principal investigator 1 Janssen Research & Development, LLC $230.00 05/28/2025 Non-covered Recipient Entity
Arizona Arthritis and Rheumatology Associates
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175166091
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $8,435.80 05/14/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH PLLC
A Multi-Center, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects with Active Psoriatic Arthritis Stratified by Prior Biologic Use (LATITUDE-PsA-3002 No dispute reported 06/30/2026 1223279756
Principal investigator 1 Eli Lilly and Company $2,373.58 04/23/2025 Non-covered Recipient Entity
AARA CLINICAL RESEARCH
A PHASE 2A, SINGLE-ARM STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3541860 IN ADULT PARTICIPANTS WITH MODERATELY-TO-SEVERELY ACTIVE RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 1187873187
Principal investigator 1 SANOFI US SERVICES INC. $600.00 04/14/2025 Non-covered Recipient Entity
Arizona Arthritis Rheumatology Research PLLC
Efficacy and Safety of SAR441344 in the Treatment of Systemic Lupus Erythematosus: A Randomized, Double Blind, Placebo-controlled, Phase 2, Proof of Concept Study No dispute reported 06/30/2026 1226083129
Principal investigator 1 Janssen Research & Development, LLC $127.00 04/07/2025 Non-covered Recipient Entity
Arizona Arthritis and Rheumatology Associates
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175165915
Principal investigator 1 Amgen Inc. $45,760.01 04/04/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH PLLC
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjgren's Syndrome With Moderate-to-severe Systemic Disease Activity No dispute reported 06/30/2026 1246639241
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $9,105.00 04/04/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH PLLC
A Multi-Center, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects with Active Psoriatic Arthritis Stratified by Prior Biologic Use (LATITUDE-PsA-3002 No dispute reported 06/30/2026 1223277606
Principal investigator 1 Janssen Research & Development, LLC $2,500.00 04/02/2025 Non-covered Recipient Entity
Arizona Arthritis and Rheumatology Associates
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175165055
Principal investigator 1 Janssen Research & Development, LLC $2,000.00 04/02/2025 Non-covered Recipient Entity
Arizona Arthritis and Rheumatology Associates
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175165092
Principal investigator 1 Janssen Research & Development, LLC $2,000.00 04/02/2025 Non-covered Recipient Entity
Arizona Arthritis and Rheumatology Associates
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175165315
Principal investigator 1 Janssen Research & Development, LLC $2,000.00 04/02/2025 Non-covered Recipient Entity
Arizona Arthritis and Rheumatology Associates
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175165368
Principal investigator 1 Janssen Research & Development, LLC $2,500.00 04/02/2025 Non-covered Recipient Entity
Arizona Arthritis and Rheumatology Associates
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175165427
Principal investigator 1 Janssen Research & Development, LLC $1,200.00 04/02/2025 Non-covered Recipient Entity
Arizona Arthritis and Rheumatology Associates
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175165498
Principal investigator 1 Janssen Research & Development, LLC $1,200.00 04/02/2025 Non-covered Recipient Entity
Arizona Arthritis and Rheumatology Associates
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175165961
Principal investigator 1 UCB SA $4,244.30 03/21/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH
A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND TOLERABILITY OF DAPIROLIZUMAB PEGOL TREATMENT IN STUDY PARTICIPANTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS No dispute reported 06/30/2026 1246658368
Principal investigator 1 Janssen Research & Development, LLC $416.00 03/07/2025 Non-covered Recipient Entity
Arizona Arthritis and Rheumatology Associates
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175165689
Principal investigator 1 Janssen Research & Development, LLC $437.00 02/27/2025 Non-covered Recipient Entity
Arizona Arthritis and Rheumatology Associates
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175165455
Principal investigator 1 Janssen Research & Development, LLC $2,456.00 02/27/2025 Non-covered Recipient Entity
Arizona Arthritis and Rheumatology Associates
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175165483
Principal investigator 1 Janssen Research & Development, LLC $2,297.10 02/27/2025 Non-covered Recipient Entity
Arizona Arthritis and Rheumatology Associates
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175165548
Principal investigator 1 UCB SA $134.00 02/27/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF DAPIROLIZUMAB PEGOL IN STUDY PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS No dispute reported 06/30/2026 1246659583
Principal investigator 1 Janssen Research & Development, LLC $75.00 02/21/2025 Non-covered Recipient Entity
Arizona Arthritis and Rheumatology Associates
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175165339
Principal investigator 1 Janssen Research & Development, LLC $75.00 02/06/2025 Non-covered Recipient Entity
Arizona Arthritis and Rheumatology Associates
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175166082
Principal investigator 1 Eli Lilly and Company $33,412.01 01/28/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH
A RANDOMIZED, CONTROLLED PRAGMATIC PHASE 3B/4 STUDY OF BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 1187876425
Principal investigator 1 Janssen Research & Development, LLC $2,674.10 01/27/2025 Non-covered Recipient Entity
Arizona Arthritis and Rheumatology Associates
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175164958
Principal investigator 1 Janssen Research & Development, LLC $1,967.00 01/27/2025 Non-covered Recipient Entity
Arizona Arthritis and Rheumatology Associates
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175165324
Principal investigator 1 Janssen Research & Development, LLC $3,122.60 01/27/2025 Non-covered Recipient Entity
Arizona Arthritis and Rheumatology Associates
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175165763
Principal investigator 1 Janssen Research & Development, LLC $1,967.00 01/27/2025 Non-covered Recipient Entity
Arizona Arthritis and Rheumatology Associates
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175166046
Principal investigator 1 Amgen Inc. $5,262.57 01/21/2025 Non-covered Recipient Entity
SHORES RHEUMATOLOGY
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjgren's Syndrome With Moderate-to-severe Systemic Disease Activity No dispute reported 06/30/2026 1246648159
Principal investigator 1 Amgen Inc. $1,545.80 01/08/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY ASSOCIATES - TUCSON - 2001 W ORANGE GROVE RD
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjgren's Syndrome With Moderate-to-severe Systemic Disease Activity No dispute reported 06/30/2026 1246639223